Celiac Disease Diagnosis

Introduction to Celiac Disease Diagnosis

The British Society of Gastroenterology guidelines provide clear interpretation criteria for celiac disease diagnosis, including definite, probable, and potential celiac disease, based on serology status and histological findings, such as villous atrophy (Marsh 3) and increased intraepithelial lymphocytes (IELs) 1
The Marsh criteria is the gold standard histological classification system for diagnosing celiac disease, categorizing small intestinal mucosal damage from type 0 (normal) through type 3 (villous atrophy), with type 3 being diagnostic of celiac disease when accompanied by positive serology, in patients with symptoms such as diarrhea and abdominal pain 1

The original Marsh classification describes the progressive immunopathological spectrum of gluten-induced mucosal changes, including normal mucosa, increased IELs, crypt hyperplasia, and villous atrophy, in patients with celiac disease, with a strength of evidence level of high 1
The Marsh-Oberhuber modification further subdivides type 3 lesions into type 3a (partial villous atrophy), type 3b (subtotal villous atrophy), and type 3c (total villous atrophy), which can aid in diagnosis and treatment decisions, with a moderate level of evidence 1

Obtain multiple biopsies (at least 6) from the second part of the duodenum or beyond, while the patient is on a gluten-containing diet, to increase the diagnostic yield, with a high level of evidence 2
Avoid duodenal bulb due to Brunner's glands and peptic changes, and ensure patient is on gluten-containing diet during biopsy, to minimize false negatives, with a moderate level of evidence 2
Celiac lesions can be patchy, requiring multiple biopsies, and a duodenal biopsy may be negative when the lesion is only present in the jejunum, highlighting the importance of thorough biopsy sampling, with a high level of evidence 1

Positive serology (particularly IgA-TG2 and EMA) with villous atrophy is diagnostic of celiac disease, with a high level of evidence 1
IgA deficiency (2% of celiac patients) requires IgG-based testing (IgG-TG2 or IgG-DGP), to avoid false negatives, with a moderate level of evidence 2
Nearly 100% of celiac patients have HLA-DQ2 (~95%) or HLA-DQ8 (~5%), and absence of these alleles provides nearly 100% negative predictive value, making HLA testing a useful tool in diagnosis, with a high level of evidence 2

Perform serologic testing (IgA-TG2, total IgA) while patient is on gluten-containing diet, to identify potential celiac disease cases, with a moderate level of evidence
If positive serology, proceed to endoscopy with multiple duodenal biopsies, to confirm diagnosis, with a high level of evidence 2
If Marsh 3 lesions with positive serology: diagnose celiac disease, with a high level of evidence 1
If Marsh 1-2 lesions with positive serology: consider probable celiac disease and trial of gluten-free diet, with a moderate level of evidence
If negative serology with villous atrophy: consider other causes and HLA testing, to rule out other conditions, with a moderate level of evidence 2